NEW YORK–(BUSINESS WIRE) June 23, 2023 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older…Original Article
FDA Approves Litfulo (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
